Haffkine Bio-Pharmaceutical Corporation Ltd. Offers Monovalent Type 1 Oral Poliomyelitis Vaccine. Haffkine Bio-Pharmaceutical Corporation Ltd. Manufactures wide range of bacterial and viral vaccines for diphtheria, tetanus, whooping cough, plague, poliomyelitis and rabies. Monovalent Type 1 Oral Poliomyelitis Vaccine is a clear, transparent, yellowish orange or light pink coloured solution. Monovalent Type 1 Oral Poliomyelitis Vaccine contains suspension of type 1 attenuated poliomyelitis virus [Sabin strain] propagated in primary monkey kidney cell cultures [P.M.K.C.C]. This vaccine may contain trace amounts of Erythromycin and Kanamycin. It fulfils WHO requirements for Monovalent Type 1 Oral Poliomyelitis Vaccine. This vaccine is indicated for Poliomyelitis Supplementary Immunisation Activities [SIAs] in children from 0 to 5 years of age, to interrupt Type 1 poliovirus transmission in remaining polio endemic areas. The routine vaccination programme should continue to use trivalent vaccines according to national policy.